Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs.Those hurdles aren't surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales after raking in record-setting revenue during the pandemic. The drugmaker has pursued deals of all sizes in recent years to build new revenue streams, such as its recently closed $10 billion acquisition of the obesity b ...